Overview

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Status:
RECRUITING

Trial end date:
2028-11-30

Target enrollment:

Participant gender:

Summary

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

Phase:

NA

Details

Lead Sponsor:

Pfizer

Treatments:

lorlatinib